Literature DB >> 1595058

Postoperative ascitic leaks: the ongoing challenge.

A S Rosemurgy1, R C Statman, C G Murphy, M H Albrink, E W McAllister.   

Abstract

BACKGROUND: The leak of ascitic fluid from surgical incisions is thought to be associated with a very high mortality rate. There have been few reports, however, focusing on the clinical characteristics, management, or mortality rates of this condition.
METHODS: During a 10-year period, 18 patients with postoperative ascitic fluid leaks were treated. All patients had ascites before surgery and all had liver disease; in 13 of the 18 patients alcoholic liver disease was the cause of ascites.
RESULTS: Ten of the 18 patients died (56%). Midline incisions were more often associated with recalcitrant leaks and fatal complications than were transverse incisions.
CONCLUSIONS: Early consideration of fascial dehiscence and prompt repair is emphasized. The most effective predictor of survival was cessation of the leak.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1595058

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  The effectiveness and appropriate management of abdominal drains in patients undergoing elective liver resection: a retrospective analysis and prospective case series.

Authors:  Kuniya Tanaka; Takafumi Kumamoto; Kazunori Nojiri; Kazuhisa Takeda; Itaru Endo
Journal:  Surg Today       Date:  2012-07-14       Impact factor: 2.549

2.  Drainage after elective hepatic resection. A randomized trial.

Authors:  J Belghiti; M Kabbej; A Sauvanet; V Vilgrain; Y Panis; F Fekete
Journal:  Ann Surg       Date:  1993-12       Impact factor: 12.969

3.  Conservative treatment versus elective repair of umbilical hernia in patients with liver cirrhosis and ascites: results of a randomized controlled trial (CRUCIAL trial).

Authors:  B de Goede; M M J van Rooijen; B J H van Kempen; W G Polak; R A de Man; P Taimr; J F Lange; H J Metselaar; G Kazemier
Journal:  Langenbecks Arch Surg       Date:  2020-11-25       Impact factor: 3.445

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.